Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Soleno Ther­a­peu­tics may have to wait longer to hear from the FDA on the po­ten­tial ap­proval of its first med­i­cine.

The Cal­i­for­nia biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.